MX2007004265A - Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino. - Google Patents

Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino.

Info

Publication number
MX2007004265A
MX2007004265A MX2007004265A MX2007004265A MX2007004265A MX 2007004265 A MX2007004265 A MX 2007004265A MX 2007004265 A MX2007004265 A MX 2007004265A MX 2007004265 A MX2007004265 A MX 2007004265A MX 2007004265 A MX2007004265 A MX 2007004265A
Authority
MX
Mexico
Prior art keywords
inflammatory bowel
disease
bowel disease
compound
cyano
Prior art date
Application number
MX2007004265A
Other languages
English (en)
Spanish (es)
Inventor
Richard D Scheyer
Scot D Styren
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MX2007004265A publication Critical patent/MX2007004265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2007004265A 2004-10-19 2005-10-18 Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino. MX2007004265A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62025504P 2004-10-19 2004-10-19
PCT/US2005/037161 WO2006044741A1 (en) 2004-10-19 2005-10-18 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
MX2007004265A true MX2007004265A (es) 2008-03-04

Family

ID=35636963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004265A MX2007004265A (es) 2004-10-19 2005-10-18 Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino.

Country Status (13)

Country Link
US (1) US20070197643A1 (2)
EP (1) EP1804782A1 (2)
JP (1) JP2008517059A (2)
KR (1) KR20070065888A (2)
CN (1) CN101043883A (2)
AU (1) AU2005295511A1 (2)
BR (1) BRPI0518205A (2)
CA (1) CA2584655A1 (2)
IL (1) IL182591A0 (2)
MX (1) MX2007004265A (2)
RU (1) RU2007118691A (2)
SG (1) SG142305A1 (2)
WO (1) WO2006044741A1 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615267A1 (en) 2005-07-11 2007-01-18 Ablation Frontiers, Inc. Low power tissue ablation system
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
NZ598744A (en) * 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
ATE269295T1 (de) * 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
EP1381356B1 (en) * 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AU2003258454A1 (en) * 2002-09-06 2004-04-30 Schebo®Biotech Ag Compounds for modulating the glycolosis enzyme complex and/or transaminase complex

Also Published As

Publication number Publication date
BRPI0518205A (pt) 2008-11-04
US20070197643A1 (en) 2007-08-23
CN101043883A (zh) 2007-09-26
SG142305A1 (en) 2008-05-28
KR20070065888A (ko) 2007-06-25
EP1804782A1 (en) 2007-07-11
JP2008517059A (ja) 2008-05-22
RU2007118691A (ru) 2008-11-27
CA2584655A1 (en) 2006-04-27
AU2005295511A1 (en) 2006-04-27
IL182591A0 (en) 2007-09-20
WO2006044741A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US20070197643A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP2002537332A (ja) 内臓痛を予防及び治療するためのガバペンチン誘導体
ES2305287T3 (es) Uso de (4'-trifluorometifenil)-amida del acido (z)-ciano-3-hidroxi-but-2-enoico para tratar la esclerosis multiple.
US6794410B2 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
BRPI0908292B1 (pt) Métodos e composições para administração oral de exenatida
JP2003522799A (ja) コポリマー１の経口、経鼻および経肺投与製剤
CN121695155A (zh) 减少与甲状腺相关的副作用的方法
KR100951540B1 (ko) 탈수초성 질병 또는 상태 치료용 약제학적 조성물
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
CN112469415B (zh) 用于预防或治疗非酒精性脂肪性肝炎的药物组合物
JP2024539930A (ja) 頂端側ナトリウム依存性輸送体阻害剤組成物
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
KR20070034070A (ko) 신경병성 통증, 섬유근통 또는 류마티스성 관절염의 치료
WO2019009359A1 (ja) 経鼻投与用医薬組成物
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
WO2025026423A1 (en) Compositions, their use and manufacture for treatment of gastrointestinal conditions
HK1106701A (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
CA2356829A1 (en) Method for treating asthma using pregabalin
CN111184706B (zh) 一种防治胆囊炎的活性药物及其用途
WO1999039703A1 (fr) Medicaments preventifs et curatifs de troubles de la muqueuse intestinale
TWI662967B (zh) 食後期之胃運動亢進劑
Tsiaoussis et al. Gallbladder fasting volume is reduced and gallbladder postprandial emptying is enhanced by intravenous erythromycin
JP2024534040A (ja) パーキンソン病の治療方法
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal